v3.26.1
The company (Tables)
 12 Months Ended
Dec. 31, 2025
Corporate information and statement of IFRS compliance [abstract]  
Disclosure of changes in share capital The tables below set out the Company’s shareholding, based on the information
available to Innate as of the date of this report, before and after the closing of the capital increase dated April 24, 2025:


◦Before closing
Shareholder
Nb of Shares[1]
%
Nb of voting rights[2]
%
Novo Nordisk A/S9,817,54611.71%9,817,54611.60%
Medimmune Limited7,485,5008.93%7,485,5008.85%
Bpifrance Participations6,389,4067.62%6,389,4067.55%
Members of the Executive Board, Supervisory Board and Leadership Team846,9441.01%911,4441.08%
Treasury shares18,5750.02%0—%
Public59,286,44070.71%59,995,08570.92%
Total83,844,411100.00%84,598,981100.00%
After closing of the capital increase:
Shareholder
Nb of Shares[1]*
%
Nb of voting rights[2]
%
Novo Nordisk A/S9,817,54610.65%9,817,54610.56%
Sanofi-Aventis Participations8,345,3879.05%8,345,3878.98%
Medimmune Limited7,485,5008.12%7,485,5008.05%
Bpifrance Participations6,389,4066.93%6,389,4066.87%
Members of the Executive Board, Supervisory Board and Leadership Team846,9440.92%911,4440.98%
Treasury shares18,5750.02%0—%
Public59,286,44064.31%59,995,08564.55%
Total92,189,798100.00%92,944,368100.00%

[1] Ordinary shares includes ordinary shares plus ordinary shares pursuant to the 2016 and 2017 free preference shares.
The table below presents the historical changes in the share capital of the Company as of December 31, 2023, 2024 and 2025, respectively:
Number of
DateNature of the TransactionsShare CapitalShare premiumCommon sharesPreferred sharesNominal value
Balance as of January 1
2023		4,011,308 379,636,745 80,212,069 14,095 €0.05 
April 14, 2023Capital increase by issuance of common shares (exercise of share warrants)728 28,955 14,550 — €0.05 
April 14, 2023Capital increase by issuance of common shares3,015 168,840 60,300 — €0.05 
April 14, 2023Capital increase by issuance of common shares (definitive acquisition of free shares )8,165 (8,165)163,293 — €0.05 
July 6, 2023Capital increase by issuance of common shares (exercise of share warrants)3,321 142,991 66,410 — €0.05 
September 18, 2023Capital increase by issuance of common shares (conversion of preferred shares in common shares)33 (33)650 (5)€0.05 
October 3, 2023Capital increase by issuance of common shares (definitive acquisition of free shares )6,403 (6,403)128,061 — 0.05 
December 15, 2023Subsciption of share warrants— 47,120 — — €— 
December 31, 2023Capital increase by issuance of common shares (definitive acquisition of free shares )10,762 (10,762)215,230 — €0.05 
December 31, 2023Share based payments— 4,255,748 — — €— 
Balance as of December 31
2023		4,043,733 384,255,036 80,860,563 14,090 €0.05 
Number of
DateNature of the TransactionsShare CapitalShare premiumCommon sharesPreferred sharesNominal value
Balance as of January 1
2024		4,043,733 384,255,036 80,860,563 14,090 €0.05 
June 10, 2024Capital increase by issuance of common shares1,905 91,440 38,100 — €0.05 
June 10, 2024Capital increase by issuance of common shares (definitive acquisition of free shares )3,437 (3,437)68,744 — €0.05 
Capital increase by issuance of common shares (exercise of share warrants)€0.05 
July 5, 2024Capital increase by issuance of common shares (conversion of preferred shares in common shares)97 (97)1,950 (15)€0.05 
December 5, 2024Capital increase by issuance of common shares91,645 2,767,677 1,832,899 — €0.05 
December 5, 2024Share issuance costs— (24,150)— — €— 
December 31, 2024Capital increase by issuance of common shares (definitive acquisition of free shares )51,404 (51,404)1,028,080 — €0.05 
December 31, 2024Share based payments— 3,944,383 — — 
Balance as of December 31
2024		4,192,221 390,979,449 83,830,336 14,075 €0.05 
Number of
DateNature of the TransactionsShare CapitalShare premiumCommon sharesPreferred sharesNominal value
Balance as of January 1, 20254,192,221 390,979,449 83,830,336 14,075 €0.05 
April 24, 2025Capital increase by issuance of common shares417,269 14,582,729 8,345,387 — €0.05 
April 24, 2025Share issuance costs(67,963)— €0.05 
May 5, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)32 (32)650 (5)€0.05 
July 3, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)355 (355)7,150 (55)€0.05 
July 17, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)32 (32)650 (5)€0.05 
July 25, 2025Subsciption of share warrants— 49,000 — — €— 
July 31, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)32 (32)650 (5)€0.05 
August 18, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)32 (32)650 (5)€0.05 
November 17, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)194 (194)3,900 (30)€0.05 
November 27, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)355 (355)7,150 (55)€0.05 
December 18, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)65 (65)1,300 (10)€0.05 
December 31, 2025Capital increase by issuance of common shares (conversion of preferred shares in common shares)76,075 (76,075)1,521,500 — —
December 31, 2025Share based payments— 2,567,446 — — —
Balance as of December 31, 20254,686,661 408,033,490 93,719,323 13,905 €0.05